BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15316094)

  • 1. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
    Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
    Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.
    Budde K; Fritsche L; Waiser J; Glander P; Slowinski T; Neumayer HH;
    Eur J Med Res; 2005 Apr; 10(4):169-74. PubMed ID: 15946913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
    Budde K; Lehne G; Winkler M; Renders L; Lison A; Fritsche L; Soulillou JP; Fauchald P; Neumayer HH; Dantal J;
    J Clin Pharmacol; 2005 Jul; 45(7):781-91. PubMed ID: 15951468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G; Schmidli H; Punch J; Tuttle-Newhall E; Mayer D; Neuhaus P; Samuel D; Nashan B; Klempnauer J; Langnas A; Calmus Y; Rogiers X; Abecassis M; Freeman R; Sloof M; Roberts J; Fischer L
    Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
    Kovarik JM; Snell GI; Valentine V; Aris R; Chan CK; Schmidli H; Pirron U
    J Heart Lung Transplant; 2006 Apr; 25(4):440-6. PubMed ID: 16563975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H; Vitko S; Pascual J; Eris J; Magee JC; Whelchel J; Civati G; Campbell S; Alves-Filho G; Bourbigot B; Garcia VD; Leone J; Esmeraldo R; Rigotti P; Cambi V; Haas T;
    Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus in pediatric de nova renal transplant patients.
    Hoyer PF; Ettenger R; Kovarik JM; Webb NJ; Lemire J; Mentser M; Mahan J; Loirat C; Niaudet P; VanDamme-Lombaerts R; Offner G; Wehr S; Moeller V; Mayer H;
    Transplantation; 2003 Jun; 75(12):2082-5. PubMed ID: 12829916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
    Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
    Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H; Hetzer R
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with everolimus.
    Augustine JJ; Hricik DE
    Transplant Proc; 2004 Mar; 36(2 Suppl):500S-503S. PubMed ID: 15041396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
    Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
    Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
    Montagnino G; Sandrini S; Iorio B; Schena FP; Carmellini M; Rigotti P; Cossu M; Altieri P; Salvadori M; Stefoni S; Corbetta G; Ponticelli C
    Nephrol Dial Transplant; 2008 Feb; 23(2):707-14. PubMed ID: 17890244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.